DOCSLIB.ORG

Evotec OAI AG Annual Report 2004 'Taking the Lead'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evotec OAI AG Annual Report 2004 'Taking the Lead' Evotec OAI AG Annual Report 2004 ‘taking the lead’ Segment overview Evotec OAI operates through three Discovery Programs business divisions: Division (DPD) > Discovery Programs Division: Evotec OAI’s Discovery Programs Division proprietary drug candidates (DPD) is developing a deep portfolio of > Discovery and Development proprietary drug candidates. With years Services: contract research and of experience in assay development, development screening, chemistry and optimisation, > Tools and Technologies|Evotec Evotec OAI has established a strong Technologies: technologies and track record of successfully identifying instruments such candidates for its customers. In its proprietary research DPD has built up extensive knowledge about diseas- es of the central nervous system (CNS) through Evotec Neurosciences (ENS) and about metabolic disorders through the joint venture with DeveloGen. Through the acquisition of full ownership interest in ENS in March 2005, the Com- pany has now established its own attrac- tive CNS pipeline. DPD plans to rapidly progress the current programmes, to ex- pand these activities and to engage in early partnerships and|or out-license the drugs at proof-of-concept to the pharma- ceutical industry which is continuously searching for novel drug candidates to fill their clinical development pipelines. Discovery and Development Tools and Technologies Services (DDS) (Evotec Technologies|ET) Evotec OAI’s Discovery and Development Evotec Technologies (ET) is developing Services (DDS) division provides drug innovative drug discovery technolo- discovery contract research and develop- gies and instruments for the pharmaceu- ment support to a large group of global tical and biotechnology industries customers and to Evotec OAI’s internal and academic research institutions. The research in the Discovery Programs Company provides cutting-edge solu- Division. DDS’ state-of-the-art industrial tions for miniaturisation, automation and scale engine attracts both biotech cus- measurement by seamlessly inte- tomers who lack expertise in a number grating hardware, software and bioware of elements in the drug discovery proc- modules. ET’s product portfolio includes esses as well as big pharmaceutical part- optical detectors for single cells and ners who wish to enhance their R&D molecules, automated liquid handling productivity. The DDS division has evolved devices, automation systems, data as one of the fastest growing solution handling and interpretation as well as providers from target to clinic through micro plates, chips and assays. The its unmatched range of integrated ca- adoption of ET’s products worldwide pabilities, a strong track record in deliver- and its biological competence pro- ing results and an outstanding customer vides ET a significant competitive ad- network. vantage in the industry. Evotec OAI overview Content Condensed key figures Evotec OAI AG 02 Highlights 2004 Page 2003 2004 ∆ 04|03 in % 04 To our shareholders Results 06 Our strategy Revenue 36 T 77,228 72,730 (5.8) R&D expenses 38 T 15,466 13,772 (11.0) Building pharmaceutical pipelines 1) 12 Segment reports Operating loss 38 T 5,106 11,759 130.3 Linking strengths Net loss 39 T 14,242 84,203 491.2 28 R&D report EBITDA 39 T 4,086 (3,246) (179.4) Shifting the portfolio Cash flow 40 T (1,333) (3,624) (171.9) 35 Status report and outlook Our performance 2004 Balance sheet data 46 Evotec OAI shares Stockholders’ equity 41 T 172,101 102,010 (40.7) 2) 50 Corporate Governance Capital expenditure 40 T 14,204 1,646 (88.4) 53 Consolidated financial statements Cash including 78 Report of the Supervisory Board marketable securities 40 T 19,471 15,277 (21.5) 80 Supervisory Board and Management Board Balance sheet total 41 T 220,919 138,534 (37.3) 82 Financial calendar and imprint Personnel data Key figures Employees as of 31|12 42 644 646 0.3 Evotec OAI worldwide Glossary Per share Result 47 (0.40) (2.30) (475.0) ) 1 Before amortisation and impairment ) 2 Purchase of fixed and intangible assets, excluding capital leases Segment overview > v = value Pharmaceutical companies create value by delivering medicines to patients. To bring new drugs to market, they are increasingly complement- ing their internal research from outside sources. The pharmaceutical industry seeks strong partners who can deliver a continuous stream of high value drug candidates to fuel new products into their clinical development pipeline. t = target Biotech companies and leading academic institutions have validated a vast number of important biological disease targets providing tremen- dous opportunities to identify innovative drugs and improve healthcare globally. Many of these targets lie idle in a bottleneck caused by limited chemistry discovery resources and funding. Unlocking their value is a major challenge of this decade. i = integration Evotec OAI unlocks the assets of biotech companies and academia with its fully inte- grated industrial discovery engine that both validates their targets and provides novel, intermediary drug candidates that are in demand by the pharmaceutical companies. Evotec OAI’s goal is to be a Value through integration leading provider of high quality drug candidates to the Pharmaceutical research and development is a highly pharmaceutical and biotech complex and integrated endeavour that creates new industry. medicines for unmet medical needs. Successful results depend upon the quality and intelligent integration of the many individual steps within the discovery part of the process. At Evotec OAI we take pride in delivering the highest industry standards in many of the essential chemical and biological research skills, concentrating our efforts on integrating these skills to help deliver high quality drug candidates to the pharmaceutical and biotech industry. 02|Highlights 04|Letter to shareholders 06|Strategy Management report: 12|Segment reports 28|R&D report 35|Status report Highlights 2004 Evotec OAI is successfully collabo- rating with numerous pharmaceutical and biotechnology companies worldwide. Selected new contracts and highlights of 2004 are illustrated on the following two pages. Noted collabo- February March rations include a new strategic part- nership with Boehringer Ingelheim, an > Evotec OAI and Toray sign > Evotec Neurosciences to integrated medicinal licence NMDA receptor NR2B expanded discovery chemistry con- chemistry, virtual screening subunit selective antagonists and compound profiling from Roche tract with Roche, the rapid progress in agreement > Evotec OAI and Panacos Metabolic Disease drug discovery with enter into medicinal chemistry agreement to design DeveloGen and the successful develop- and optimise novel anti-HIV compounds ment of Evotec Neurosciences. > Evotec Neurosciences com- pletes € 25 million Series A financing August September > Seikagaku selects Evotec OAI > Evotec Neurosciences and as assay development Evotec OAI enter into joint and screening partner drug discovery collaboration > Second Metabolic Disease with Boehringer Ingelheim compound advanced to identify GPCR modulator- into lead optimisation in based new medicines DeveloGen joint venture > Evotec Technologies and QIAGEN demonstrate significant benefits of com- bining high-content cellular imaging systems with RNAi applications 46|Shares 50|Corporate Governance 53|Consolidated financial statements 78|Report of the Supervisory Board 02|03 April May June July > Evotec OAI increases shares in > Evotec OAI and Roche enter > NeuroNova selects > Evotec OAI successfully parenteral formulation into strategic global discovery Evotec OAI as their assay increased its share capital subsidiary ProPharma to 81% chemistry agreement development and > Biogen Idec selects > Evotec OAI enters into > Guilford Pharmaceuticals screening partner Evotec OAI as a service integrated virtual screening selects Evotec OAI as > Evotec OAI undergoes provider for process and medicinal chemistry their assay development and successful FDA inspection research & development agreement with Fujisawa screening partner > Morphochem selects > Evotec OAI to expand agree- > Evotec OAI enters into discov- Evotec OAI as a partner for the ment with Oxford Bioscience ery agreement with Nuvios chemical and pharmaceutical Partners through integration development of its dual action of its new rational drug design antibiotic Oxaquin® platform, EVOrationale™ > Evotec OAI to apply new rational drug design platform, EVOrationale™, to high priority research programme from ActivBiotics October December > ALTANA Pharma selects > Evotec Technologies provides Evotec OAI as partner for a EVOscreen® and Opera™ to kinase lead identification Korea programme 02|Highlights 04|Letter to shareholders 06|Strategy Management report: 12|Segment reports 28|R&D report 35|Status report To our shareholders 2004 was a difficult year for Evotec OAI in terms of top and bottom line performance. Our contract research (Discovery and Development Services, DDS) and technology (Evotec Technol- ogies, ET) groups are still considered the best in the industry; however, in a stagnant pharmaceutical outsourcing market aggravated by the weak U.S.-Dollar, consistent growth as a pure service company is a challenge. With that said, we are optimistic about the future prospects for Evotec OAI. 2005 will be a critical year in the development of our company and we have successfully taken a number of measures necessary to keep Evotec OAI on a continued growth track: Increased emphasis on proprietary Joern Aldag President and Chief Executive Officer drug
Load more

Recommended publications
  • MDAX—2019 Supervisory Board Study Key Insights from This Year’S Analysis by Russell Reynolds Associates
    MDAX—2019 Supervisory Board Study Key insights from this year’s analysis by Russell Reynolds Associates Summary Over the past year, Germany's MDAX companies have experienced significant change. The number of companies in the index increased by 10, bringing the overall total to 60. Moreover, 11 "old economy" firms, including Jungheinrich, Krones, Leoni, Salzgitter and Schaeffler, were ousted by pharma, med and biotech risers, such as Evotec, Morphosys, Qiagen, Sartorius and Siemens Healthineers, as well as "new economy" powerhouses like Dialog, Nemetschek, Software AG, Telefonica D, and United Internet. This was also an exceptional election year, with 106 shareholder representative positions expiring. All positions were filled. A total of 67 board members were re-elected, while 36 were replaced. The three remaining roles were absorbed by changes to board sizes. Female shareholder representation surpasses 30 percent For the first time, the share of female shareholder representatives surpassed the required quota, reaching 30.6 percent. Including employee representatives, women now make up 32 percent of supervisory board members. A total of three boards are now chaired by women. However, there is still a major gender discrepancy concerning positions of power when comparing chairpersonships and especially executive board positions. Only four companies can boast more than 30 percent of female executives, while 40 MDAX companies do not have a single woman in a leadership role. Accelerated increase in digital directors The number of digital directors on MDAX supervisory boards showed a significant 30 percent year- on-year increase. However, digital expertise is still unevenly spread in the MDAX. Seven companies have three or more digital directors, while 57 percent of boards completely lack digital expertise.
    [Show full text]
  • Fund Holdings
    Wilmington International Fund as of 7/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS ISHARES MSCI CANADA ETF 3.48% TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD 2.61% DREYFUS GOVT CASH MGMT-I 1.83% SAMSUNG ELECTRONICS CO LTD 1.79% SPDR S&P GLOBAL NATURAL RESOURCES ETF 1.67% MSCI INDIA FUTURE SEP21 1.58% TENCENT HOLDINGS LTD 1.39% ASML HOLDING NV 1.29% DSV PANALPINA A/S 0.99% HDFC BANK LTD 0.86% AIA GROUP LTD 0.86% ALIBABA GROUP HOLDING LTD 0.82% TECHTRONIC INDUSTRIES CO LTD 0.79% JAMES HARDIE INDUSTRIES PLC 0.78% DREYFUS GOVT CASH MGMT-I 0.75% INFINEON TECHNOLOGIES AG 0.74% SIKA AG 0.72% NOVO NORDISK A/S 0.71% BHP GROUP LTD 0.69% PARTNERS GROUP HOLDING AG 0.65% NAVER CORP 0.61% HUTCHMED CHINA LTD 0.59% LVMH MOET HENNESSY LOUIS VUITTON SE 0.59% TOYOTA MOTOR CORP 0.59% HEXAGON AB 0.57% SAP SE 0.57% SK MATERIALS CO LTD 0.55% MEDIATEK INC 0.55% ADIDAS AG 0.54% ZALANDO SE 0.54% RIO TINTO LTD 0.52% MERIDA INDUSTRY CO LTD 0.52% HITACHI LTD 0.51% CSL LTD 0.51% SONY GROUP CORP 0.50% ATLAS COPCO AB 0.49% DASSAULT SYSTEMES SE 0.49% OVERSEA-CHINESE BANKING CORP LTD 0.49% KINGSPAN GROUP PLC 0.48% L'OREAL SA 0.48% ASSA ABLOY AB 0.46% JD.COM INC 0.46% RESMED INC 0.44% COLOPLAST A/S 0.44% CRODA INTERNATIONAL PLC 0.41% AUSTRALIA & NEW ZEALAND BANKING GROUP LTD 0.41% STRAUMANN HOLDING AG 0.41% AMBU A/S 0.40% LG CHEM LTD 0.40% LVMH MOET HENNESSY LOUIS VUITTON SE 0.39% SOFTBANK GROUP CORP 0.39% NOVARTIS AG 0.38% HONDA MOTOR CO LTD 0.37% TOMRA SYSTEMS ASA 0.37% IMCD NV 0.37% HONG KONG EXCHANGES & CLEARING LTD 0.36% AGC INC 0.36% ADYEN
    [Show full text]
  • Translation of Financial Statements As of 31 December 2020 And
    Translation of Financial Statements as of 31 December 2020 and Management Report Evotec SE Exhibit 1 Evotec SE, Hamburg Statement of financial position as of 31 December 2020 Assets 31.12.2020 31.12.2019 Equity and liabilities 31.12.2020 31.12.2019 EUR EUR EUR EUR A. Equity A. Fixed assets I. Subscribed capital 163.914.741,00 150.902.578,00 I. Intangible assets ./. nominal value Treasury shares -249.915,00 -249.915,00 Purchased franchises, industrial and similar rights 163.664.826,00 150.652.663,00 and assets, and licenses in such rights and assets 1.194.857,45 4.082.552,01 II. Capital reserves 482.139.820,51 243.587.164,27 II. Property, plant and equipment III. Reserve for treasury shares 249.915,00 249.915,00 1. Land, land rights and buildings, including buildings on third-party land 1.572.345,71 1.804.727,38 IV. Accumulated loss -100.132.424,27 -75.948.394,50 2. Plant and machinery 12.251.848,90 11.732.420,10 3. Other equipment, furniture and fixtures 1.160.417,33 1.035.981,29 545.922.137,24 318.541.347,77 4. Prepayments and assets under construction 1.315.392,83 1.118.311,65 16.300.004,77 15.691.440,42 III. Financial assets B. Provisions 1. Shares in affiliates 334.222.810,07 334.187.810,07 1. Provisions for pensions and similar obligations 169.091,00 166.780,00 2. Loans to affiliates 132.335.498,54 2.
    [Show full text]
  • FACTSHEET - AS of 28-Sep-2021 Solactive Mittelstand & Midcap Deutschland Index (TRN)
    FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) DESCRIPTION The Index reflects the net total return performance of 70 medium/smaller capitalisation companies incorporated in Germany. Weights are based on free float market capitalisation and are increased if significant holdings in a company can be attributed to currentmgmtor company founders. HISTORICAL PERFORMANCE 350 300 250 200 150 100 50 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Jan-2020 Jan-2022 Solactive Mittelstand & MidCap Deutschland Index (TRN) CHARACTERISTICS ISIN / WKN DE000SLA1MN9 / SLA1MN Base Value / Base Date 100 Points / 19.09.2008 Bloomberg / Reuters MTTLSTRN Index / .MTTLSTRN Last Price 342.52 Index Calculator Solactive AG Dividends Included (Performance Index) Index Type Equity Calculation 08:00am to 06:00pm (CET), every 15 seconds Index Currency EUR History Available daily back to 19.09.2008 Index Members 70 FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -3.69% 3.12% 7.26% 27.72% 12.73% 242.52% Performance (p.a.) - - - - - 9.91% Volatility (p.a.) 13.05% 12.12% 12.48% 13.60% 12.90% 21.43% High 357.49 357.49 357.49 357.49 357.49 357.49 Low 342.52 329.86 315.93 251.01 305.77 52.12 Sharpe Ratio -2.77 1.14 1.27 2.11 1.40 0.49 Max. Drawdown -4.19% -4.19% -4.19% -9.62% -5.56% -47.88% VaR 95 \ 99 -21.5% \ -35.8% -34.5% \ -64.0% CVaR 95 \ 99 -31.5% \ -46.8% -53.5% \ -89.0% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES EUR 100.0% DE
    [Show full text]
  • Evotec Kauft US-Firma Für 256 Mio. Euro
    Interview Cellact-Chefin Nalân Utku über den erfolgreichen Verkauf ihrer virtuellen Firma an Mundi- Wirtschaft. Technologie. Leben. 23. Jahrgang. 9|2017. pharma ISSN 1435-5272 | A 49017 25 JAHRE Morphosys feiert doppelt LESEPROBE DIGITALE MEDIZIN Deutschland will aufholen Expansion SPEZIAL Biosimilars drängen in Markt Evotec kauft US-Firma WAHL 2017 für 256 Mio. Euro Biopolitik in den Wahlprogrammen Bei Amgen sind biologische Arzneimittel in Qualität verwurzelt und werden von Zuverlässigkeit genährt. Eine solide Qualitätskontrolle und zuverlässige Versorgung sind genau so wichtig wie wissenschaftliche Innovationen. Seit mehr als drei Jahrzehnten wird bei Amgen jedes Medikament mit Engagement, Leidenschaft und dem Streben nach Perfektion hergestellt. Darum finden Sie bei Amgen die Biologika, die für die Behandlung Ihrer Patienten so enorm wichtig sind. Und das auch für die zukünftigen Generationen. Weitere Informationen über Amgens Engagement für eine gleichbleibende 8\HSP[p[\UKa\]LYSpZZPNL=LYZVYN\UNÄUKLU:PL\U[LY biotechnologybyamgen.de ©2013 Amgen Inc. Alle Rechte vorbehalten. AMG-DEU-AMG-021-2014-January-P (1/2014) 02_tk12_15_Amgen.indd 2 02.12.2015 15:22:22 Uhr European Biotechnology NETWORK Bundestagswahl I Stellt Euch vor, es ist Wahlkampf, und keiner kriegt‘s mit. Bis zum Redaktionsschluss jedenfalls konnte von Kampf um Wählerstimmen in Deutschland keine Rede sein. Die Regierende gibt wie üblich das Präsidenten-Surrogat, während es dem herausfordernden Dampfplauderer noch nicht einmal gelingt, aus dem Schatten seiner ver- staubten Partei zu treten. Die Grünen haben ein ernstes Verkalkungsproblem, die Populisten vom rechten und linken Rand verkünden ihr übliches dummes Zeug. Bei der FDP lässt sich noch nicht sagen, ob sie sich im Par- lament trauen wird, die von vielen vermisste Stimme der Andreas Mietzsch wirtschaftlichen Sachkenntnis und Vernunft zu erheben.
    [Show full text]
  • Authorizations for Capital Raisings and Convertible Bond Issues
    Authorizations for Capital Raisings, Convertible Bond Issues and Share Repurchases (2019) German DAX® and MDAX® Companies clearygottlieb.com Preface This booklet presents a summary overview of authorizations for capital raisings and convertible bond issuances of all German DAX® and MDAX® companies based on their 2019 annual general meetings.* Responding to inquiries from clients and friends, this booklet now also covers authorizations for share repurchases of all German DAX® and MDAX® companies, also based on their 2019 annual general meetings. The amount of any authorized capital reflected in this booklet takes into account any issuance of shares out of authorized capital entered into the commercial register prior to August 1, 2019. The amount of any convertible bond authorization and underlying conditional capital reflected in this booklet takes into account the issuance of any convertible bonds based on such authorization prior to August 1, 2019 and the amount of conditional capital underlying such convertible bonds. The number of any shares repurchased under a buy-back program reflected in this booklet takes into account the publicly announced share repurchases of the respective issuer until August 1, 2019. Consistent with the nature of the booklet as a summary overview, the information on the authorizations for capital raisings, convertible bond issuances and share repurchases provided herein is limited to the key parameters of the relevant authorized capital, convertible bond authorization, conditional capital and share repurchase authorization. A more detailed analysis of, e.g., the feasibility of a certain capital raising or share repurchase will always require a comprehensive review of the complete wording of the authorization(s) concerned.
    [Show full text]
  • Corporate Governance Presentation Forward-Looking Statements
    April 2021 Corporate Governance Presentation Forward-Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding tafasitamab’s ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of Monjuvi. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent
    [Show full text]
  • FTSE Publications
    2 FTSE Russell Publications FTSE Developed Eurozone Minimum 19 August 2021 Variance Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 1&1 AG 0.14 GERMANY Erste Group Bank 0.11 AUSTRIA Muenchener Rueckversicherungs Reg 0.03 GERMANY A2A 0.22 ITALY EssilorLuxottica 0.47 FRANCE Naturgy Energy Group SA 0.38 SPAIN Acciona S.A. 0.1 SPAIN Eurazeo 0.13 FRANCE Neoen S.A. 0.37 FRANCE Ackermans & Van Haaren 0.76 BELGIUM Eurofins Scienti 0.77 FRANCE Neste Oyj 0.36 FINLAND Adidas 0.14 GERMANY Euronext 0.83 FRANCE NN Group 0.07 NETHERLANDS Adyen 0.72 NETHERLANDS Evonik Industries AG 0.1 GERMANY Nokia 0.32 FINLAND Aena SME SA 0.05 SPAIN Evotec 0.35 GERMANY Nokian Tyres 0.26 FINLAND Ageas 0.1 BELGIUM Ferrari NV 0.46 ITALY Nordea Bank Abp 0.2 FINLAND Ahold Delhaize 1.31 NETHERLANDS Ferrovial 0.26 SPAIN Orange 0.67 FRANCE AIB Group 0.03 IRELAND Fielmann 0.68 GERMANY Orion B 1.15 FINLAND Air Liquide 0.54 FRANCE Finecobank 0.24 ITALY ORPEA 0.47 FRANCE Akzo Nobel 0.71 NETHERLANDS Fortum 0.24 FINLAND Pernod Ricard 0.92 FRANCE Ald SA 0.15 FRANCE Fresenius Medical Care 1.04 GERMANY Pirelli & C 0.19 ITALY Allianz SE 0.03 GERMANY Fresenius SE & Co KGaA 0.39 GERMANY Plastic Omnium 0.18 FRANCE Alstom 0.56 FRANCE Fuchs Petrolub Pref SE 0.36 GERMANY ProSiebenSat.1 Media SE 0.19 GERMANY Amplifon 0.26 ITALY Fuchs Petrolub SE 0.32 GERMANY Prosus 0.33 NETHERLANDS Amundi 0.12 FRANCE Galapagos Genomics NV 0.1 NETHERLANDS Proximus 0.76 BELGIUM Andritz 0.6 AUSTRIA Galp Energia SGPS SA 0.19 PORTUGAL Prysmian 0.22 ITALY Argenx S.E 0.25 BELGIUM GEA Group AG 0.17 GERMANY Publicis Groupe 0.36 FRANCE Arkema 0.06 FRANCE Gecina 0.4 FRANCE Puma 0.06 GERMANY Aroundtown SA 0.36 GERMANY Generali 0.41 ITALY Qiagen Nv 1.2 GERMANY ASML Holding 0.25 NETHERLANDS Getlink 0.06 FRANCE Raiffeisen Bank International 0.18 AUSTRIA ASR Nederland 0.04 NETHERLANDS Glanbia 1.08 IRELAND Randstad NV 0.13 NETHERLANDS Atos SE 0.17 FRANCE Grandvision B.V.
    [Show full text]
  • Introductory Report, and We Will Only Report Top-Level Data
    Bertrand Delsuc, Ph.D. biotechradar.eu / Biotellytics September 15th, 2019 THE EUROPEAN LANDSCAPE OF LISTED BIOTECH COMPANIES 2018 REVIEW September 2019 Author: Bertrand Delsuc The European landscape of listed biotech companies: 2018 review This review is an introduction to the universe covered by Biotellytics, publisher of biotechradar.eu, a business intelligence service on the landscape of the European biotech companies listed on the main European stock exchanges. This service aims at providing insights and data at company level for investors, as well as consolidated data for the European level for life sciences professionals. This review will form a basis for more content to be released in the future. This document is intended for a broad audience but more particularly people who are already specialized in the life sciences, without being familiar with the European biotech landscape, and notably the listed side. After a definition of our universe, and a presentation of our selection, we will provide a global overview of the landscape for 2018, based on the following items: IPOs, M&As, R&D pipeline, commercial products, market data, employment, financing and other financial metrics, and deals. All these data will be broken down by country or by (country) cluster, when relevant, in order to have a minimum number of companies for each presented data. Belgium (BE) and the Netherlands (NL) will be taken together, as well as UK and Ireland (IE). Norway (NO) and Finland (FI) will also be gathered into a cluster. The same way, Italia (IT) and Spain (ES) will form the “Southern Europe” cluster. We will end by a snapshot of the characteristics of a “typical” European public biotech company, at the end of 2018.
    [Show full text]
  • Drug Evolution Riding High
    COMPANY PORTRAIT_Evotec Drug evolution riding high Evotec’s history illustrates that biotechnology made in Germany can set standards worldwide. The Max Planck Society is one of the company’s founders and continues to shape it to this day. TEXT DIRK BÖTTCHER n the early 1990s, few people had Evotec is one of Germany’s most suc- until that time, scientists had focused heard of evolutionary molecular cessful biotechnology stories. The com- their research on individual molecules, biology, this field was a source of pany is growing at a breathtaking pace, using their knowledge of biochemistry inspiration for entrepreneurs and utilizing unique technologies, and its to try to achieve specific binding prop- investors. Co-founded by the No- approach based on highly-automated, erties – and, by extension, a desired ef- bel IPrize Laureate Manfred Eigen from industrial-scale translational research fect. Just what might they achieve, the Max Planck Institute for Biophysi- has revolutionized the industry. Most however, if they could investigate a cal Chemistry in Goettingen in 1993, notably, the company has been shaped vast number of these molecules using Hamburg-based Evotec Biosystems set by some of the most remarkable scien- a quasi-evolutionary process in a single out to investigate pharmaceutical sub- tists of our time. device? Eigen’s vision, previously un- stances using the technique Eigen had imaginable, would come to fruition. developed. In a nutshell, the technique FOURTEEN SITES, SIX COUNTRIES, Visiting Evotec in Hamburg today is based on utilizing evolutionary pro- 3,000 EMPLOYEES shows how brilliant his idea was. Es- cesses such as selection by random tablished as a small company with a variations to research and develop First and foremost, they include Man- starting capital of EUR 7 million and a drugs.
    [Show full text]
  • Holdings—Artisan Global Discovery Fund
    Artisan Global Discovery Fund Holdings As of 30 September 2020 Portfolio Holdings Quantity Security Name/Description Price Book Total Market Value Book Pct Assets (%) 61,633 Advanced Micro Devices Inc 81.99 5,053,289.67 2.40 1,115 Adyen NV 1,842.86 2,054,785.76 0.98 11,245 Allegro.eu SA 11.12 125,093.13 0.06 47,964 Aluflexpack AG 26.70 1,280,523.22 0.61 40,677 Ameren Corp 79.08 3,216,737.16 1.53 13,195 Arista Networks Inc 206.93 2,730,441.35 1.30 37,090 Ascendis Pharma A/S 154.32 5,723,728.80 2.72 25,854 Atlassian Corp PLC 181.79 4,699,998.66 2.24 136 Belimo Holding AG 7,552.34 1,027,118.03 0.49 39,307 Blackline Inc 89.63 3,523,086.41 1.68 137,264 Boston Scientific Corp 38.21 5,244,857.44 2.49 99,644 Burberry Group PLC 20.02 1,995,090.27 0.95 15,339 Burlington Stores Inc 206.09 3,161,214.51 1.50 47,843 Centene Corp 58.33 2,790,682.18 1.33 31,532 Ceridian HCM Holding Inc 82.65 2,606,119.80 1.24 5,803 Cintas Corp 332.83 1,931,412.49 0.92 166,141 Clarivate PLC 30.99 5,148,709.59 2.45 40,197 Cognex Corp 65.10 2,616,824.70 1.24 17,749 Cree Inc 63.74 1,131,321.26 0.54 28,674 CTS Eventim AG & Co KGaA 48.37 1,387,055.43 0.66 5,189 DexCom Inc 412.23 2,139,061.47 1.02 243,627 E.ON SE 11.05 2,691,755.32 1.28 4,470 Eurofins Scientific SE 791.64 3,538,616.24 1.68 47,571 Evotec SE 26.46 1,258,689.63 0.60 24,951 First Republic Bank 109.06 2,721,156.06 1.29 56,389 Fortive Corp 76.21 4,297,405.69 2.04 13,860 Genmab A/S 363.11 5,032,736.97 2.39 20,003 Gerresheimer AG 111.90 2,238,285.33 1.06 46,806 Global Payments Inc 177.58 8,311,809.48 3.95 29,434 Guidewire
    [Show full text]
  • [Iito] in a Nutshell
    Visibility for your Business – In a Nutshell Banner Advertising at [LSE] Life-Sciences-Europe.com Ad Offer 0 Visibility for your brand, your business model, and products & services 0 Visibility to global decision makers interested in the European life sciences Visibility for Your Business 0 Visibility 24/7, all year long, to senior managers who stay & return to our portals 0 Several banners at the same time offer you a powerful storytelling approach 0 Putting your content marketing back into the ad: open, transparent & effective [iito] Concept 0 We created one single entry-point to the whole European life sciences 0 The most powerful & time-efficient way to keep track of what’s going on in the Best Content + Readers European business for free; with news, deals, persons, organisations covered = Best Advertising 0 Content selection completely separated from advertising (no “pay-to-play”) 0 High-quality content attracts senior level readers who come, stay & return 0 The only pictures on the portals are openly labelled banner ads, guaranteeing perfect attention without annoying the readers Web Portal 0 [LSE] Life-Sciences-Europe.com (including six regional subportals) 0 The world’s most comprehensive free European life science business info source [LSE] Life-Sciences-Europe 0 100,000 web pages online: news, organisations, deals, persons, products & events 0 210,000 monthly page views and 65,000 monthly visits* 0 Average number of pages viewed per visit: more than 3 0 Average time per visit: more than 4 minutes 0 90% of visitors enter the portals directly (i.e., not via search engines) Search Engines 0 Excellent Google rankings: on 1st page of Google search results..
    [Show full text]